ESSA Pharma Inc 2025年季度报告

FORM 10-Q (Mark One)☐QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934For the quarterly period ended December 31, 2024or ☐TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period fromtoCommission file number: 001-37410 ESSA Pharma Inc. (Exact name of registrant as specified in its charter) British Columbia, Canada98-1250703(State or other jurisdiction of(I.R.S. Employerincorporation or organization)Identification Number)Suite 720, 999 West BroadwayVancouver, BC V5Z 1K5(Address of principal executive offices, including zip code)Registrant’s telephone number, including area code: (778) 331-0962 Securities registered pursuant to Section 12(b) of the Act: Name of each exchange on which registered Nasdaq Capital Market Indicate by check mark whether the registrant: (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Actof 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subjectto such filing requirements for the past 90 days. Yes ☐ No ☐ Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant toRule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was requiredto submit such files). Yes ☐ No ☐ Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reportingcompany, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and“emerging growth company” in Rule 12b-2 of the Exchange Act. Accelerated filerSmaller reporting companyEmerging growth company If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying withany new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐ Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Securities Exchange Act of 1934). Yes ☐ No ☐ The number of outstanding Common Shares of the registrant, no par value per share, as of February 10, 2025 was 44,388,550. ESSA PHARMA INC.QUARTERLY REPORT ON FORM 10-QFor the Quarter Ended December 31, 2024Table of ContentsPART I. FINANCIAL INFORMATION6Item 1.Financial Statements and Supplementary Data6Condensed Consolidated Interim Balance Sheets as of December 31, 2024 and September 30,20247Condensed Consolidated Interim Statements of Operations and Comprehensive Loss for the threeand three months ended December 31, 2024 and 20238Condensed Consolidated Interim Statements of Cash Flows for the three months ended December31, 2024 and 20239Condensed Consolidated Interim Statement of Changes in Shareholders’ Equity for the three andthree months ended December 31, 2024 and 202310Notes to the Condensed Consolidated Interim Financial Statements11Item 2.Management’s Discussion and Analysis of Financial Condition and Results of Operations19Item 3.Quantitative and Qualitative Disclosure About Market Risk44Item 4.Controls and Procedures44PART II. OTHER INFORMATION45Item 1.Legal Proceedings45Item 1A. Risk Factors45Item 2.Unregistered Sales of Equity Securities and Use of Proceeds45Item 3.Defaults Upon Senior Securities45Item 4.Mine Safety Disclosures45Item 5.Other Information45Item 6.Exhibits, Financial Statement Schedules46SIGNATURES47 CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS This Quarterly Report on Form 10-Q includes “forward-looking statements” within the meaning of the U.S.Private Securities Litigation Reform Act of 1995 and “forward-looking information” within the meaning ofCanadiansecurities laws,or collectively,forward-looking statements.Forward-looking statements includestatements that may relate to our plans, objectives, goals, strategies, future events, future revenue or performance,capital expenditures, financing needs and other information that is not historical information. Many of thesestatements appear, in particular, under the headings “Business,” “Risk Factors,” and “Management’s Discussionand Analysis of Financial Condition and Results of Operations.” Forward-looking statements can often beidentified by the use of terminology such as “subject to,” “believe,” “anticipate,” “plan,” “expect,” “intend,”“estimate,” “project,” “may,” “might,” “will,” “should,” “would,” “could,” “hope,” “can,” the negatives thereof,variations thereon and similar expressions, or by discussions of strategy. Such forward-looking statements involveknown and unknown risks, uncertainties and other factors that may cause the Company’s actual results,performance or achievements to be materially different from any future results, performance or